Article Details
Retrieved on: 2022-08-15 12:27:52
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca's drug targets patients with HER2-positive metastatic breast cancer. In its 600-patient trial called DESTINY-Breast02, Enhertu was ...
Article found on: www.thisismoney.co.uk
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here